Elsevier Inc.

SHERPA: Unknown

People

  1. Ladanyi
    Ladanyi
  2. Kris
    Kris
  3. Riely
    Riely
  4. Rekhtman
    Rekhtman
  5. Drilon
    Drilon
  6. Arcila
    Arcila
  7. Offin
    Offin
  8. Rusch
    Rusch
  9. Yu
    Yu
  10. Berger
    Berger

Groups

  1. GSK Faculty (91)
  2. Human Oncology and Pathogenesis Program (91)
  3. Tow Center for Developmental Oncology (TCDO) (91)
  4. Department of Medicine (66)
  5. Solid Tumor Oncology Division (66)
  6. Thoracic Oncology (64)
  7. Sloan Kettering Institute Postdocs (26)
  8. Surgery (22)
  9. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (20)
  10. Biostatistics Service (19)
Search Within
  1. "Marc Ladanyi"
Formats
  1. Journal Article (53)
  2. Meeting Abstract (37)
  3. Conference Paper (1)
Groups
  1. GSK Faculty (91)
  2. Human Oncology and Pathogenesis Program (91)
  3. Tow Center for Developmental Oncology (TCDO) (91)
  4. Department of Medicine (66)
  5. Solid Tumor Oncology Division (66)
  6. Thoracic Oncology (64)

More Groups

People
  1. Marc Ladanyi (91)
  2. Mark Kris (37)
  3. Gregory Riely (32)
  4. Maria Arcila (21)
  5. Natasha Rekhtman (21)
  6. Alexander Drilon (17)

More People

Years
  1. 2024 (2)
  2. 2023 (7)
  3. 2022 (5)
  4. 2021 (4)
  5. 2020 (4)
  6. 2019 (13)

More Years

Publications
  1. Journal of Thoracic Oncology (71)
  2. Human Pathology (7)
  3. European Journal of Cancer (4)
  4. Cancer Genetics (1)
  5. Clinical Lung Cancer (1)
  6. Clinics in Laboratory Medicine (1)

More Publications

Results (91)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Microsatellite instability and mismatch repair deficiency define a distinct subset of lung cancers characterized by smoking exposure, high tumor mutational burden, and recurrent somatic MLH1 inactivation
    Journal Article

    Yang, S. R.; Gedvilaite, E.; Ptashkin, R.; Chang, J.; Ziegler, J.; Mata, D. A.; Villafania, L. B.; Nafa, K.; Hechtman, J. F.; Benayed, R.; more...
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • HER4 and EGFR activate cell signaling in NRG1 fusion-driven cancers: Implications for HER2-HER3-specific versus pan-HER targeting strategies
    Journal Article

    Udagawa, H.; Nilsson, M. B.; Robichaux, J. P.; He, J.; Poteete, A.; Jiang, H.; Heeke, S.; Elamin, Y. Y.; Shibata, Y.; Matsumoto, S.; more...
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of patients with EGFR-mutant lung cancer with acquired BRAF alterations
    Meeting Abstract

    Sui, J.; Yang, S. R.; Bowman, A. S.; Vankayala, P.; Falcon, C.; Somwar, R.; Drilon, A. E.; Riely, G. J.; Kris, M. G.; Ladanyi, M.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Microsatellite instability defines a subset of lung cancers with smoking exposure, high tumor mutational burden and MLH1 inactivation
    Meeting Abstract

    Yang, S. R.; Gedvilaite, E.; Ptashkin, R.; Chang, J.; Ziegler, J.; Mata, D.; Villafania, L. B.; Nafa, K.; Hechtman, J. F.; Benhamida, J.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Impact of aneuploidy and chromosome 9p loss on tumor immune microenvironment and immune checkpoint inhibitor efficacy in NSCLC
    Journal Article

    Alessi, J. V.; Wang, X.; Elkrief, A.; Ricciuti, B.; Li, Y. Y.; Gupta, H.; Spurr, L. F.; Rizvi, H.; Luo, J.; Pecci, F.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Combination therapy with MDM2 and MEK inhibitors is effective in patient-derived models of lung adenocarcinoma with concurrent oncogenic drivers and MDM2 amplification
    Journal Article

    Elkrief, A.; Odintsov, I.; Markov, V.; Caeser, R.; Sobczuk, P.; Tischfield, S. E.; Bhanot, U.; Vanderbilt, C. M.; Cheng, E. H.; Drilon, A.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Clinicopathologic and genomic factors impacting efficacy of first-line chemoimmunotherapy in advanced NSCLC
    Journal Article

    Alessi, J. V.; Elkrief, A.; Ricciuti, B.; Wang, X.; Cortellini, A.; Vaz, V. R.; Lamberti, G.; Frias, R. L.; Venkatraman, D.; Fulgenzi, C. A. M.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228
    Journal Article

    Paik, P. K.; Fan, P. D.; Qeriqi, B.; Namakydoust, A.; Daly, B.; Ahn, L.; Kim, R.; Plodkowski, A.; Ni, A.; Chang, J.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers
    Journal Article

    Choudhury, N. J.; Marra, A.; Sui, J. S. Y.; Flynn, J.; Yang, S. R.; Falcon, C. J.; Selenica, P.; Schoenfeld, A. J.; Rekhtman, N.; Gomez, D.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Vepafestinib is effective in preclinical models of sarcomas with RET fusion including a brain metastasis model
    Meeting Abstract

    Odintsov, I.; Liu, A.; Khodos, I.; Chang, Q.; Giuliano, C.; Mattar, M.; Vojnic, M.; Bonifacio, A.; De Stanchina, E.; Lovati, E.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save